Close
Help




JOURNAL

Clinical Medicine Insights: Pathology

Pharmacotherapeutic Options for Visceral Leishmaniasis - Current Scenario

Submit a Paper


Clinical Medicine Insights: Pathology 2009:2 1-4

Published on 23 Jan 2009


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Pathology

Abstract

Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as the gold standard treatment for VL. But due to the increasing unresponsiveness, to this drug various other drugs were tried and are still being tried. Pentamidine is very toxic and has been discarded of late. Amphotericin B and its lipid formulations are very effective but require hospital admission and monitoring. Oral drugs like Miltefosine have already been launched. An amino glycoside Paromomycin and another oral drug Sitamaquine are in the pipe line. Interferon gamma has been used with discouraging results.



Downloads

PDF  (198.10 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Pathology
I experienced rapid and fair peer review and fast article publication. The competent editorial and production staff at Libertas Academica were attentive to every detail and were great at communicating with us during the review and publication process. Thank you for your great service.
Dr Geetanjali Gupta (Department of Pathology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube